FDA Grants Priority Review to Nivolumab Plus Ipilimumab to Treat NSCLC
Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news